Last updated: February 27, 2026
What is the indication and market positioning of NDC 16714-0964?
NDC 16714-0964 is a proprietary formulation of pegcetacoplan, marketed under the brand name "Aspaveli." It is approved by the FDA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare acquired hematopoietic stem cell disorder characterized by complement-mediated hemolysis.
Aspaveli is intravascular complement inhibitor that targets C3, preventing hemolysis and thrombotic complications. The drug was approved in July 2021. Its competitive positioning involves offering an alternative to earlier complement inhibitors like eculizumab (Soliris) and ravulizumab (Ultomyst).
Market size and growth drivers
Current Market Size
In 2022, the global PNH drug market was valued at approximately $650 million, with the U.S. accounting for roughly 75% of sales. The number of diagnosed PNH patients in the U.S. is estimated at 2,000 to 3,000.
| Metric |
Estimate |
Source |
| U.S. diagnosed PNH patients |
2,000 – 3,000 |
[1] |
| Estimated global PNH population (all stages) |
5,000 – 7,000 |
[2] |
| Market value of PNH drugs (2022) |
$650 million |
[3] |
Market Growth Catalysts
- Increasing diagnosis rates due to better awareness and diagnostic tools.
- Expanding treatment coverage and reimbursement.
- New treatment options targeting complement C3, including Aspaveli.
- Improvements in patient quality of life with C3 inhibitors versus earlier therapies.
Competitive Landscape
| Product |
Approval Year |
Target |
Market Share (2022) |
Price (per year) |
Notes |
| Soliris (eculizumab) |
2007 |
C5 |
60% |
$500,000 |
First FDA-approved PNH treatment |
| Ultomyst (ravulizumab) |
2018 |
C5 |
25% |
$460,000 |
Longer dosing interval |
| Aspaveli (pegcetacoplan) |
2021 |
C3 |
15% |
$385,000 |
New alternative targeting C3 |
Price projection analysis
Current Pricing
- Eculizumab: approximately $500,000 annually.
- Ravulizumab: approximately $460,000 annually.
- Aspaveli: approximately $385,000 annually.
Compared to existing therapies, Aspaveli's pricing is slightly lower, reflecting competitive market positioning and potential market share gains through clinical advantages.
Future Price Trends (Next 5 Years)
Considering factors such as manufacturer pricing strategies, payer negotiations, and market dynamics:
| Year |
Projected Price (USD) |
Change from 2022 |
Comments |
| 2023 |
$385,000 |
0% |
Market stabilization |
| 2024 |
$380,000 |
-1.3% |
Price erosion due to competition |
| 2025 |
$375,000 |
-2.6% |
Increased competitive pressure |
| 2026 |
$370,000 |
-3.9% |
Payer negotiations and market expansion |
| 2027 |
$365,000 |
-5.2% |
Cost pressures and generic threats |
Note: Payer negotiations, pricing pressures, and clinical differentiation influence these projections.
Sales Volume and Revenue Forecast
Assuming a gradual increase in prescriber base and market share:
| Year |
Estimated Patients on Aspaveli |
Market Share |
Annual Revenue (USD) |
Notes |
| 2022 |
600 |
5% |
$231 million |
Launch phase |
| 2023 |
900 |
7.5% |
$347 million |
Market penetration increase |
| 2024 |
1,200 |
10% |
$456 million |
Growing adoption |
| 2025 |
1,500 |
12.5% |
$563 million |
Increased competition |
| 2026 |
1,800 |
15% |
$664 million |
Expansion into new markets |
Key factors influencing future value
- Approval of biosimilars or generics after patent expiry.
- New pipeline drugs offering superior efficacy or reduced cost.
- Shifts in payer reimbursement policies favoring cost-effective therapies.
- Additional indications or expanded labeling.
Risks and uncertainties
- Unexpected clinical trial outcomes affecting approval or market share.
- Regulatory changes impacting pricing or market access.
- Market consolidation or new entrants disrupting current competition.
- Patient outliers favoring older, established therapies.
Conclusion
NDC 16714-0964 (Aspaveli) is positioned as a mid-priced, innovative option for PNH. The drug captures a niche between high-cost, established therapies and emerging competitors. Projections suggest a gradual price decline aligned with market expansion. Long-term revenue depends on prescriber uptake, competitive developments, and payer dynamics.
Key Takeaways
- Aspaveli’s current annual price is approximately $385,000, with projected reductions over five years due to market pressures.
- The potential U.S. market can reach $664 million annually by 2026, assuming increased adoption.
- Competitive landscape remains firm, with Soliris and Ultomyst maintaining significant market share.
- Overall market growth driven by improved diagnosis, reimbursement, and clinical benefits.
- Final revenue and market share outcomes hinge on clinical data, regulatory decisions, and payer strategies.
FAQs
1. What factors could cause Aspaveli’s price to increase?
Demand surge due to clinical advantages over existing therapies or regulatory changes expanding indications could enable higher pricing.
2. How do biosimilars impact the PNH market?
Once patents expire, biosimilars could reduce prices sharply, impacting revenue projections.
3. What are the key differentiators for Aspaveli over other PNH treatments?
Targeting C3 theoretically prevents all complement-mediated hemolysis and thrombosis, offering a potential for improved clinical outcomes.
4. Are there other pipeline therapies that could challenge Aspaveli?
Yes, drugs targeting different complement components or novel mechanisms can disrupt market share.
5. How does payer coverage influence the market?
Reimbursement decisions and formulary placements directly impact drug accessibility and sales volumes.
References
[1] Sharma, S., et al. (2022). Diagnosis and incidence of PNH. Blood Reviews.
[2] Parker, C., et al. (2021). Epidemiology of PNH. Haematologica.
[3] EvaluatePharma. (2022). Oncology and rare disease market valuations.
